Coronary Artery Bypass Surgery. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: Patients in group A received 1500 cc Ringer as a prime solution during preparation of (CPB). Intervention 2: Patients in group B received Valuven1500 ml, 130/04 (hydroxyethyl starch) d
Treatment - Drugs
Patients in group A received 1500 cc Ringer as a prime solution during preparation of (CPB).
Patients in group B received Valuven1500 ml, 130/04 (hydroxyethyl starch) during preparation of CPB. Monitoring of vital signs is recorded.
Sponsors
Vice Chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients undergoing coronary artery bypass graft (CABG) for the first time. Exclusion criteria: undergoing cardiac surgery for the second time; emergency coronary artery bypass; coagulation disorders prior to surgery; the preoperative clopidogrel (Plavix); congestive heart failure before surgery; renal failure before surgery (creatinine greater than (1 / 3) with a previous history of heart surgery; heart failure; coagulation disorders including abnormal PT and PTT, INR, PLAT; kidney disease included high chromium 1.3 and taking Plavix (clopidogrel).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding. Timepoint: during and after surgery. Method of measurement: Observasion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lab data (CR - Na-K -HB- hematocrit- PT- PTT-INR ). Timepoint: before surgery and 24 hours after surgery in the ICU. Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe allahyari
Shiraz University of Medical Sciences
Outcome results
None listed